
    
      Quizartinib is metabolized primarily by CYP3A. Therefore, co-administration of quizartinib
      with CYP3A inducers may decrease quizartinib exposure. This study will assess the effect of a
      moderate CYP3A inducer efavirenz on the single dose (60 mg) quizartinib pharmacokinetics in
      healthy participants.
    
  